Seek­ing an edge in the glob­al I/O race, Al­pham­ab On­col­o­gy loads up $100M-plus from mar­quee back­ers

Al­pham­ab On­col­o­gy be­lieves it has what it takes to stand out from the del­uge of check­point in­hibitors cur­rent­ly in de­vel­op­ment — not just in Chi­na but glob­al­ly. A syn­di­cate of well-heeled in­vestors now shares that con­fi­dence, in­fus­ing more than $100 mil­lion to fu­el an am­bi­tious dri­ve through the clin­ic.

Ad­van­tech, PAG and Chi­na Ven­ture Cap­i­tal Fund led the Se­ries A, which is ex­pect­ed to sup­port Al­pham­ab’s lead as­set, KN035, all the way up to reg­is­tra­tional tri­als and fund late-stage pro­grams for three oth­er clin­i­cal drug can­di­dates. Or­biMed, Her­itage Provider Net­work and Jan­chor Part­ners al­so chipped in.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.